(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a kidney and bladder cancers oral abstract session. Dr. Tian Zhang discussed the ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a kidney and bladder cancers oral abstract ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, was host to a biomarkers in kidney cancer session. Dr. David McDermott discussed the ongoing ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the session Advancing Perioperative Treatment Options for Localized Muscle-Invasive ...

In the CheckMate 274 study, adjuvant nivolumab demonstrated a significant improvement in disease-free survival (DFS) and showed a trend toward improved overall survival (OS) in an unselected ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 th and June 3 rd, 2025, was host to a biomarkers in kidney cancer session. Dr.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to a State ...

There were 22 men with progressive mCRPC enrolled, the median age at enrollment was 66 years (range 52-80), the median PSA at original diagnosis was 82 ng/mL (range 5-3,648), 55% had a Gleason score 9 ...

Notably, treatment usage trends from a Bladder Cancer Advocacy Network (BCAN) survey presented at GU ASCO 2025 revealed that only 1–5% of patients reported having seen a radiation oncologist and only ...

ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Geoffrey Johnson discussing SECuRE, a dose escalation/expansion study to assess the anti-tumor ...

ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Shilpa Gupta discussing FGFR3 alteration status and outcomes with immune checkpoint inhibitors in patients with ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer session and a presentation by Dr. April Rose discussing a ctDNA–directed phase II study of carboplatin in patients with ...